In addition, our data indicated that RSK but not CDK inhibition remains effective in suppressing Rb-deficient cancer growth (Figure 7), highlighting that RSK inhibition may be a targeted therapy to treat Rb-deficient CRPC. This evidence concerns the gene RPS6KA3 and cancer.